ArticleFrontiers in neuroscience2026
Fatigue relief: the contribution of non-invasive neuromodulation (FAREviaNM).
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatigue is a universal and constructive experience, yet chronic fatigue-defined as a persistent lack of energy that limits daily life as assessed by modified Fatigue Impact Scale (mFIS)-remains nowadays a symptom waiting for effective mitigation. Evidence across neurological, oncological, and psychosocial conditions shows that fatigue shares a common neurophysiological substrate: disrupted sensory-motor imbalances and network synchrony that can be targeted by established interventions-physical activity, mindfulness, yoga, and cognitive-behavioral therapy. Within this landscape, non-invasive neuromodulation stands out as an effective and safe tool to restore sensorimotor balance to integrate behavioral interventions. The Faremus protocol, based on five daily sessions of 15-min bilateral anodic transcranial Direct Current Stimulation (tDCS) over the somatosensory cortex, has shown consistent clinical benefits in multiple sclerosis: an average 26% reduction in fatigue severity, persisting for weeks or months, with excellent tolerability and home-use feasibility. Converging meta-analyses, neurophysiological central and behavioral investigations, and reviews confirm the reproducibility and mechanistic validity of this approach, positioning neuromodulation among the most promising evidence-based strategies in supporting fatigue relief. This perspective highlights neuromodulation as a transversal instrument to counter fatigue across conditions, and as a cornerstone of integrated, multidisciplinary strategies aimed at preserving brain plasticity, enhancing resilience, and restoring sustained well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.